OverviewZogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$39.65 + 0.65
Data as of 10/19/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Investor Events More
Friday, September 29, 2017 8:30 a.m. ET
Zogenix Conference Call to Discuss Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Tuesday, August 8, 2017 4:30 p.m. ET
Q2 2017 Zogenix, Inc. Earnings Conference Call